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Quantitative Phosphoproteomics 
Reveals a Role for Collapsin 
Response Mediator Protein 2 in 
PDGF-Induced Cell Migration
Adil R. Sarhan  1,2, Justyna Szyroka1, Shabana Begum1, Michael G. Tomlinson1,  
Neil A. Hotchin1, John K. Heath1 & Debbie L. Cunningham  1
The Platelet Derived Growth Factor (PDGF) family of ligands have well established functions in the 
induction of cell proliferation and migration during development, tissue homeostasis and interactions 
between tumours and stroma. However, the mechanisms by which these actions are executed are 
incompletely understood. Here we report a differential phosphoproteomics study, using a SILAC 
approach, of PDGF-stimulated mouse embryonic fibroblasts (MEFs). 116 phospho-sites were identified 
as up-regulated and 45 down-regulated in response to PDGF stimulation. These encompass proteins 
involved in cell adhesion, cytoskeleton regulation and vesicle-mediated transport, significantly 
expanding the range of proteins implicated in PDGF signalling pathways. Included in the down-
regulated class was the microtubule bundling protein Collapsin Response Mediator Protein 2 (CRMP2). 
In response to stimulation with PDGF, CRMP2 was dephosphorylated on Thr514, an event known to 
increase CRMP2 activity. This was reversed in the presence of micromolar concentrations of the protein 
phosphatase inhibitor okadaic acid, implicating PDGF-induced activation of protein phosphatase 
1 (PP1) in CRMP2 regulation. Depletion of CRMP2 resulted in impairment of PDGF-mediated cell 
migration in an in vitro wound healing assay. These results show that CRMP2 is required for PDGF-
directed cell migration in vitro.
Platelet Derived Growth Factor (PDGF) was first identified in platelet extracts as a potent mitogen for fibro-
blasts and endothelial cells1. The PDGF family of ligands comprises four related gene products: PDGFA, PDGFB, 
PDGFC and PDGFD which can form both homodimers and heterodimers providing a repertoire of PDGF iso-
forms2. The PDGF family of ligands elicit their biological effects by interacting with two structurally related 
high affinity receptors of the tyrosine kinase family: PDGFR alpha and PDGFR beta3. PDGF-AA, AB, BB and 
CC induce PDGFR alpha homo-dimerisation; PDGF-BB and DD induce formation of PDGFR beta homodi-
mers, and PDGF-AB, BB, CC and DD induce formation of PDGFR alpha/PDGFR beta heterodimers2. PDGF-BB 
homodimers are therefore universal PDGFR ligands capable of eliciting the full repertoire of PDGFR-mediated 
biological responses.
PDGF receptors are expressed by cells of mesenchymal origin and the cognate PDGF ligands are expressed 
by overlying epithelial cells indicative of paracrine signalling from epithelium to the underlying mesenchyme. 
For example, in the lung, PDGFR alpha is expressed in the lung mesenchyme and PDGFA is expressed in the 
epithelium4. This pattern is seen in multiple organs and tissues such as gut, kidney, gonads, somites and nervous 
system5. Extensive genetic studies of PDGF and PDGFR function in the mouse confirms that PDGF signalling 
from epithelial cells via PDGFRs is absolutely required for the expansion and migration of specific mesenchymal 
cell populations6. For example, in the kidney, PDGF signalling is required both for the multiplication of mesangial 
cell precursors and their migration into the glomerular space5. In the lung, PDGF is required for the expansion 
of myofibroblasts and their migration along the alveolar epithelium during lung morphogenesis7. In the central 
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nervous system (CNS) oligodendrocyte precursor (O2A) cells require PDGF signalling both for population 
expansion and migration through the spinal cord8.
PDGF signalling also has significant functions in adult tissue homeostasis and regeneration, acting on cells 
of mesenchymal origin. PDGF is an established mitogen and chemoattractant for mesenchymal derived cells in 
vitro9 and has been studied for its ability to promote wound healing through promoting the migration, prolifera-
tion and extracellular matrix deposition by fibroblasts10. Ectopic expression of PDGFB in the kidney glomerulus 
induces expansion of bone marrow derived mesenchymal cells to form a severe mesanagial glomerulopathy and 
fibrosis11. PDGF-BB is a mitogen for vascular smooth muscle cells and activation of PDGF signalling is required 
for pulmonary arterial hypertension (PAH) and pulmonary arterial remodelling12.
The PDGF signalling axis is also implicated in regulation of tumour/stromal cell interactions13, 14. PDGF-BB 
produced by tumours of epithelial origin acts upon adjacent connective tissue cells, pericytes and vascular smooth 
muscle cells to regulate tumour angiogenesis and tumour-associated fibrosis15. PDGF-activated perivascular 
cells also promote metastasis via tumour-associated macrophages and act on tumour cells that have undergone 
epithelial-mesenchymal transition (EMT) to promote migration through the extracellular matrix16, 17.
Despite the biological significance of these activities, little is known about the downstream intracellu-
lar pathways that mediate these responses beyond canonical RTK signalling pathways such as PLC, AKT and 
MAPK/ERK2. To gain further insight into how PDGFs mediate their biological effects we analysed a differen-
tial phosphoproteomics dataset of PDGF-stimulated mouse embryo fibroblasts (MEFs)18. This shows that, 
in MEFs, PDGFR activation elicits a broad range of phosphorylation events mediated by downstream Ser/
Thr kinases which impact on mediators of cytoskeletal function and cell motility. In particular, we show that 
Collapsin response mediator protein-2 (CRMP2) is dephosphorylated in response to PDGF and is required for 
PDGF-induced cell migration. CRMP2 (also known as dihydropyrimidinase-like 2) is highly expressed in the 
nervous system and mediates cellular responses downstream of ephrins, neurotrophins and semaphorins, such as 
neuronal polarity, growth and axonal guidance19, 20.
Collectively these results significantly expand the range of proteins and phosphorylation events implicated in 
PDGF signalling pathways and reveal potential new targets for therapeutic intervention in PDGF signalling. They 
also reveal a role for CRMP2 in PDGF-induced cell migration which has broad implications for tissue repair and 
tumour development.
Results
PDGF-induced changes in the phosphoproteome. We have recently published quantitative SILAC 
proteomics data identifying changes in the phosphoproteome and proteome of mouse embryonic fibroblasts 
(MEFs) due to the absence of the intracellular phosphatase domain of Leukocyte Common Antigen-related 
(LAR) protein tyrosine phosphatase (PRIDE Accession PXD00254518, 21). As part of our analysis of LAR function 
WT MEFs were stimulated with PDGF, and here we have reanalysed this part of the dataset to identify novel 
PDGF-dependent phosphorylation events. Full details of the experimental setup and procedures used to obtain 
the phosphoproteomics and proteomics datasets have been previously described18. Methodology relevant to the 
PDGF-dependent dataset are summarised in Fig. 1A. The Pearson’s correlation coefficient for the phosphopeptide 
ratios measured across the three biological replicates ranged from 0.77 to 0.93 indicating good biological repro-
ducibility (Fig. 1B). Within the proteomic dataset, a total of 703 proteins were identified in two or more biological 
replicates. No significant differences in protein abundance were observed between unstimulated and PDGF stim-
ulated (7 min) cells (Fig. 1C). In the phosphoproteome dataset, 989 phosphosites from 611 proteins were detected 
with high localization scores (localization probability >0.75; score difference >5) in three or more experimental 
replicates (Supplementary Table S1). Within the phosphoproteome dataset, we identified 896 (90.6%) serine, 76 
(7.7%) threonine and 17 (1.7%) tyrosine phosphorylation sites (Fig. 1D). These results are an accurate reflection 
of the relative abundance of serine:threonine:tyrosine phosphorylation events in the cell, previously reported 
to be 88:11:1, and are comparable to those detected downstream of other receptor tyrosine kinases22, 23. Being a 
tyrosine kinase, activation of PDGFR will initiate cell signalling via tyrosine phosphorylation. PDGF-induced 
tyrosine phosphorylation events have been previously studied using enrichment strategies to increase the rela-
tive abundance of tyrosine phosphorylated peptides24, 25. As our aim was to gain an understanding of the global 
signalling landscape regulated by PDGF our enrichment strategy was not selective for either serine, threonine 
or tyrosine, enabling novel insight into the breadth of biological processes regulated by PDGF. From the 989 
phosphopeptides identified, 161 showed a significant change in phosphorylation status upon PDGF stimulation 
(p < 0.05; >1.5-fold change) (Fig. 2; Supplementary Table S2). A total of 116 phosphosites were upregulated and 
45 downregulated upon PDGF treatment. Cellular compartment analysis revealed that these PDGF-regulated 
phosphosites are present on proteins localised throughout the cell, indicating the diversity of PDGF signalling 
(Fig. 3).
Within this dataset we identified proteins that have previously been shown to be involved in PDGF signalling. 
For example, the ERK1/2 MAP kinases have been extensively studied and shown to be hyperphosphorylated 
in response to growth factors such as PDGF26–28. In agreement with these studies, we found increased phos-
phorylation of ERK1 on Tyr205 (L+PDGF 7min/M−PDGF; 15.10) and Thr203 (L+PDGF/M−PDGF; 14.13), and ERK2 on 
Tyr185 (L+PDGF/M−PDGF; 16.77). The phosphorylation of these sites on ERK1/2 is essential for kinase activity. 
Phosphorylated ERK1/2 mediates diverse physiological functions such as cell growth, survival, cell adhesion, 
migration and differentiation26–28. We have also identified an increase in the phosphorylation of Bcl2-associated 
agonist of cell death (BAD) at Ser136 upon PDGF stimulation (Supplementary Table S2). This site is a target for 
Akt downstream of PDGF and phosphorylation of Ser136 on BAD leads to enhanced cell survival29.
Novel PDGF-regulated phosphosites. From 161 phosphosites, we identified 110 (67%) that have not 
previously been reported as PDGF-regulated sites (PhosphoSitePlus)30 and are therefore considered novel. Within 
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the phosphoproteomics data set we observed that phosphorylation of Ser303 on insulin receptor substrate 2 
(IRS2) increased upon PDGF stimulation (Fig. 2). IRS2 is an adaptor protein that binds to the insulin receptor 
and regulates insulin signalling pathways. PKC isoforms, β and δ, or angiotensin II can induce phosphorylation 
of Ser303 on IRS2 in endothelial cells leading to inhibition of insulin signalling31. This suggests a novel role for 
PDGF as a negative regulator of insulin signalling, possibly via PKC, known to be activated downstream of PDGF 
through PLCγ32, 33.
After ERK1/2, the next most significant increase in phosphorylation was observed for Ser72 of Ras-related 
protein Rab7a (Fig. 2). Rab7a is a small GTPase involved in the regulation of endo-lysosomal trafficking34. 
Phosphorylation of Rab7a on Ser72 inactivates the protein, thereby impairing the recruitment to endosomal 
membranes and delaying the transport of EGFR from early to late endosomes35. This suggests that PDGFR acti-
vates an as yet unidentified kinase which phosphorylates Ser72 on Rab7a indicating an intersection between two 
major RTKs, PDGFR and EGFR in the regulation of endocytosis. In addition, we observed increased phospho-
rylation of Slit-Robo GTPase-activating protein 3 (srGAP3) on Ser858 (Supplementary Table S2), a RhoGAP that 
functions downstream of the Robo receptor and is involved in the development of the nervous system36, 37. This 
site is phosphorylated by protein kinase A (PKA), promoting GAP activity towards Rac1 and inhibition of actin 
reorganisation in neurons38.
Figure 1. Global quantitative proteomics and phosphoproteomics of PDGF signalling in mouse embryo 
fibroblasts (MEFs). (A) Schematic overview of experimental design. SILAC labelled MEFs were stimulated with 
PDGF for 7 min (+) or left unstimulated (−). (B) Heat map of Pearson correlation coefficients and multi scatter 
plots demonstrating reproducibility between the phosphoproteome of biological and technical replicates. (C) 
Volcano plots showing the ratio (log2 fold change) and significance (−log10 Benjamini-Hochberg adjusted p-
value) of the proteome dataset. (D) Numbers of serine, threonine and tyrosine phosphorylation sites identified 
within our PDGF-regulated phosphoproteome dataset.
www.nature.com/scientificreports/
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Following stimulation, 45 novel PDGF-regulated phosphosites were observed to be significantly down-
regulated including Rho-associated protein kinase 2 (ROCK2; Ser1362), Neurofibromin (NF1; Ser2517), 
CLIP-associated protein 1 (CLASP1; Ser1193), Parva (Ser14), collapsin response mediator protein 2 (CRMP2; 
Thr514) and collapsin response mediator protein 4 (CRMP4; Thr514) (Figs 2 and 3; Supplementary Table S2). 
These proteins are mainly involved in regulation of nervous system homeostasis including development, axon 
formation and growth cone guidance39–44, suggesting a common set of PDGF effectors exist in both fibroblasts 
and the nervous system and demonstrating that, in addition to the autophosphorylation and phosphorylation of 
proteins downstream of PDGFR, PDGF can also induce the dephosphorylation of key effectors, some of which 
regulate cell motility.
Functional analysis of the PDGF-regulated phosphoproteome. Gene Ontology (GO) analysis 
of the phosphoproteins regulated by PDGF revealed a number of enriched GO biological processes (Fig. 4A; 
Supplementary Table S3). The dominant enriched GO terms were associated with cytoskeletal organisation, 
MAP kinase signalling, regulation of microtubules and cell adhesion, all processes involved in cell migration. 
Actin cytoskeleton and microtubule proteins enriched in our phosphoproteome dataset include LIM domain and 
actin-binding protein 1 (Lima1), Rho guanine nucleotide exchange factor 17 (Arhgef17), Band 4.1-like protein 1 
(Epb41l1) and Stathmin (Stmn1) (Supplementary Table S3). We observed an increase in abundance of phospho-
peptides belonging to these proteins in response to PDGF stimulation (Supplementary Table S2). We also note the 
enrichment of biological processes associated with cell adhesion. Reticulon-4 (Rtn4; also known as Nogo), a pro-
tein involved in the regulation of neuron development such as neurite growth and axon-axon adhesion45, 46 was 
phosphorylated on Ser105 in response to PDGF stimulation (Supplementary Table S2). Paxillin (PXN), an adap-
tor protein involved in modulation of focal adhesions and cell adhesion pathways, is one of the PDGF-regulated 
proteins47, 48. PDGF is known to regulate PXN activity by promoting the phosphorylation of Tyr11849–51. We have 
not identified this site in our phosphoproteomics dataset, but did identify an increase in phosphorylation of Ser83 
(Supplementary Table S2). It has been reported that p38MAPK and ERK1/2 can phosphorylate PXN at Ser83 to 
regulate neurite extension and chemotaxis in neurons52, 53.
KEGG pathway analysis of PDGF-regulated proteins revealed enrichment of signalling pathways implicated in 
cell migration including focal adhesion, regulation of actin cytoskeleton, adherens junctions and transendothelial 
cell migration (Fig. 4B; Supplementary Table S4)54–56. In addition, KEGG analysis of the dataset also identified 
neurotrophin signalling and axon guidance as PDGF-regulated processes (Fig. 4B). To identify which kinases are 
activated upon PDGF stimulation, we used the Kinase Enrichment Analysis (KEA) tool57. KEA is a web-based 
software tool for the prediction of kinase-substrate interactions and links mammalian proteins with the upstream 
kinases that potentially phosphorylate them. KEA analysis revealed a significant enrichment of substrates for 
ribosomal protein S6 kinase (RSK2) (Fig. 4C; Supplementary Table S5). RSK2 promotes cell motility and inva-
sion by mediating the activity of integrins and actin cytoskeleton rearrangement58–61. RSK2 can also promote 
migration in epithelial cells through the FGFR2-p38 kinase axis pathway62. KEA analysis also identified other 
over-represented kinases including dual specificity mitogen-activated protein kinase kinase (MEK1) and c-Jun 
N-terminal kinase (JNK1) (Fig. 4C). The activities of both kinases are known to be regulated by growth factors 
such as PDGF and they are involved in regulation of many cellular functions including cell migration63, 64.
CRMP2 is a novel PDGF-regulated protein. We elected to further analyse the role of collapsin response 
mediator protein 2 (CRMP2) as an example of a novel PDGF-induced dephosphorylation target found within 
Figure 2. Volcano plots showing the magnitude and significance of differential phosphopeptide abundance in 
PDGF-stimulated versus unstimulated cells. Phosphopeptides are deemed significantly up- or down-regulated 
if they have an adjusted p value < 0.05 and exhibit a >1.5 fold-change in abundance.
www.nature.com/scientificreports/
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our dataset. CRMP2 regulates cytoskeletal remodelling, neurotransmission and axon guidance via its ability to 
promote microtubule assembly65–67. Consistent with this, GSK3β has been shown to phosphorylate CRMP2 at 
Thr509, Thr514 and Ser518 thereby inhibiting CRMP2 activity leading to microtubule depolymerization and 
destabilization68, 69. Within our dataset a doubly phosphorylated peptide from CRMP2 (pThr514; pSer518) was 
significantly downregulated following PDGF stimulation (Fig. 5A; Supplementary Table S2). Western blotting 
with a phosphospecific antibody recognising the highly conserved Thr514 residue confirmed that phosphoryla-
tion of CRMP2 at Thr514 was significantly decreased following PDGF stimulation compared to non-stimulated 
cells (Fig. 5B–D). These data clearly show that PDGF regulates the dephosphorylation of CRMP2 at Thr514, an 
event known to activate the protein.
It has been previously shown that PP1 or PP2A can dephosphorylate CRMP2 at Ser518, Thr514 or Thr50970, 71. 
We therefore tested the effect of okadaic acid on CRMP2 phosphorylation at Thr514 following PDGF stimu-
lation in MEFs. PP2A is inhibited at low concentrations (<1 μM) of okadaic acid, whereas higher concentra-
tions (>1 μM) inhibit PP172, 73. Western blot analysis showed no significant changes in PDGF-regulated CRMP2 
dephosphorylation when okadaic acid was added at low (0.01 μM or 1 μM) concentrations (Fig. 6A). However, 
higher concentrations of okadaic acid (1.5 μM) inhibited the dephosphorylation of CRMP2 at Thr514 in response 
to PDGF stimulation (Fig. 6A,B). Together, these observations suggest that PDGF signalling acts via PP1 to 
dephosphorylate CRMP2 at Thr514.
Figure 3. PDGF-regulated proteins and phosphosites. Proteins containing PDGF-regulated phosphosites 
were clustered according to their subcellular localisations as listed in the COMPARTMENTS database. PDGF-
regulated phosphosites on each protein are shown in blue and those that are novel PDGF-regulated sites are 
bordered in red.
www.nature.com/scientificreports/
6Scientific RepoRts | 7: 3970  | DOI:10.1038/s41598-017-04015-x
CRMP2 depletion inhibits cell migration in MEFs. CRMP2 has been widely studied in the nervous 
system where it regulates neuronal migration and axon guidance74, 75. CRMP2 also regulates polarisation and 
migration of T lymphocytes within the immune system76, 77. However, the regulation of cell migration by CRMP2 
outside the nervous and immune systems has not been studied. PDGF induced cell migration has been widely 
Figure 4. PDGF regulates distinct biological processes and signalling pathways. (A) Proteins containing 
the 161 PDGF regulated phosphosites were analysed in REVIGO to identify enriched GO Terms. Enriched 
biological processes are visualised as a Tree map. Clusters of related terms are displayed using the same colour 
and the size of the box corresponds to the −log10 p-value in that category. (B) Proteins containing the PDGF-
regulated phosphosites were analysed in DAVID to identify enriched KEGG pathways. (C) PDGF-regulated 
phosphopeptides were searched using the Kinase enrichment analysis (KEA) tool. The network shows the 
enriched predicted upstream kinases and the node size corresponds to the number of PDGF-regulated 
phosphopeptides predicted to be phosphorylated by that kinase.
www.nature.com/scientificreports/
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studied in fibroblasts, revealing roles for Rac1, MAPK/ERK and JNK kinases64, 78. To establish if CRMP2 has a role 
in PDGF induced cell migration in MEFs we examined the consequences of RNAi-mediated depletion of CRMP2 
in a standard in vitro scratch wound healing assay. Confluent MEFs were transfected with a CRMP2 directed 
SMARTpool of siRNAs and non-silencing control siRNA, serum starved and wounded in the presence of PDGF 
(Fig. 7). The results of this experiment clearly show that siRNA mediated depletion of CRMP2 (Fig. 7A) signif-
icantly inhibits the rate of wound closure in the presence of PDGF (Fig. 7B,C). This was confirmed using three 
individual siRNAs against CRMP2 (Supplementary Fig. S1). These observations confirm that CRMP2, identified 
in our dataset as a novel PDGF downstream effector, is required for PDGF-stimulated cell migration in MEFs.
Figure 5. CRMP2 is a novel PDGF-regulated protein. (A) Tandem mass spectrum of the CRMP2 T514/S518 
phosphopeptide. (B) Schematic representation of the domain structure of CRMP2 and the highly conserved 
amino acid motif containing Thr514. (C) MEFs were stimulated with 20 ng/mL PDGF for 7 min. CRMP2, 
CRMP2 Thr514, ERK1/2, ERK 1/2 Thr202/Tyr204 and Alix in whole cell lysates were analysed by Western 
blotting. For uncropped images of blots see Supplementary Fig. S2. (D) Western blots were quantified and ratios 
of pCRMP2 to CRMP2 were plotted (**P < 0.01).
Figure 6. PP1 dephosphorylates CRMP2 Thr514 in response to PDGF stimulation. (A) MEFs were incubated 
with either DMSO or okadaic acid (0.01 μM, 1 μM or 1.5 μM) for 30 min prior to stimulation with 20 ng/
mL PDGF for 7 min. CRMP2, CRMP2 Thr514, total phospho-threonine and Alix were analysed by Western 
blotting. For uncropped images of blots see Supplementary Fig. S3. (B) Western blots were quantified and ratios 
of pCRMP2 to CRMP2 were plotted (*P < 0.05).
www.nature.com/scientificreports/
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Discussion
PDGF ligands and their cognate receptors are firmly established as key mediators of mesenchymal cell migration 
in developmental, homeostatic and pathological processes2–5. However, the downstream effectors of the PDGF 
pathway are incompletely characterised. In order to identify PDGF-regulated protein phosphorylation events and 
expand the range of PDGF mediators, we undertook a study of PDGF-stimulated MEFs using a differential phos-
phoproteomics approach18. The aim of this study was to significantly expand the repertoire of PDGF pathway 
effectors and to identify novel candidates that might mediate PDGF induced cell migration. Here we report the 
identification of 989 phosphosites from 611 proteins in our screen. Out of these, 116 phosphopeptides were 
significantly upregulated in PDGF-stimulated cells, many of which are novel PDGF-regulated phosphosites. 
Phosphoproteins regulated by PDGF play a role in cellular signalling pathways that mediate cell adhesion, endo-
cytosis and vesicular trafficking, cytoskeletal organization and nuclear function.
We also report the identification of 45 phosphopeptides that are significantly down-regulated in response 
to PDGF stimulation. These include proteins such as CLASP1 and CRMP2. CRMP2 is of interest as an effector 
of PDGF-mediated cell migration as it has a well- established role as mediator of axon guidance, growth cone 
collapse and cell migration in neurons67, 75, 79. Phosphoproteomic and western blotting analysis indicated that, 
in MEFs, PDGF mediates dephosphorylation of CRMP2 at Thr514. In neuronal cells this site is phosphorylated 
by GSK3β leading to destabilization of microtubules and neurite degeneration, whereas the dephosphorylated 
form of CRMP2 Thr514 promotes microtubule stabilisation and sustains neurite outgrowth68, 69, 80. This indicates 
that dephosphorylation of CRMP2 involves the activation of a protein phosphatase(s). We showed that micro-
molar concentrations of okadaic acid, a serine/threonine phosphatase inhibitor, restored the phosphorylation of 
CRMP2 at Thr514. This is most likely due to preferential inhibition of protein phosphatase 1 (PP1)72, 73. CRMP2 is 
not however dephosphorylated in non-stimulated cells showing that PDGF pathway activation is essential for the 
CRMP2 directed activity of this phosphatase. Given the intersection of CRMP2 in neuronal cells and MEFs we 
were interested to learn if CRMP2 was required for PDGF induced cell migration. Depletion of CRMP2 resulted 
Figure 7. CRMP2 plays a role in PDGF-induced cell migration. (A) Representative western blot showing levels 
of CRMP2 in MEFs following transient transfection with non-silencing control siRNA (NSC), or with CRMP2 
siRNA (siCRMP2). Alix was used as a loading control. For uncropped images of blots see Supplementary 
Fig. S4. (B) Transfected MEFs were wounded using an automated scratch maker and stimulated with 20 ng/
ml PDGF. Images of five separate wounds were taken at 0, 10, 20, 30, 40, 50, and 60 h post wounding using the 
IncuCyte ZOOM imaging system. (C) The percentage of the wound open at each time point was quantified 
using ImageJ. Data are presented as average % wound open and error bars represent the standard error of the 
mean (n = 3; **P < 0.01, ***P < 0.001).
www.nature.com/scientificreports/
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in impairment of cell migration in a scratch wound assay in the presence of PDGF showing that it is required for 
PDGF induced cell migration in MEFs.
Our quantitative phosphoproteomics study has significantly expanded the known repertoire of PDGF effec-
tors and provided a resource for further experimental studies. The novelty of our findings is highlighted by the 
fact that we have identified a role for CRMP2 in PDGF-regulated cell migration, a fundamental biological process 
closely linked to developmental processes and progression of disease.
Methods
Phosphoproteomics and bioinformatics. Details of the experimental setup for the quantitative phos-
phoproteomics experiments have been previously described18. Within the MaxQuant output, phosphorylation 
sites were considered to be localised correctly if the localisation probability was at least 0.75 (75%) and the score 
difference at least 5. Significance testing was performed in the Perseus software environment, which is part of 
MaxQuant (Perseus version 1.5.0.15; www.perseus.framework.org), using a Student’s t-test on log 2 transformed 
ratios and controlled with a Benjamini-Hochberg FDR threshold of 0.05. Peptides quantified in three or more 
experimental repeats were deemed significantly changed and regulated by PDGF if they had a p-value of <0.05 
and a ratio of <0.667 or >1.5 (at least a 1.5-fold change in abundance). The COMPARTMENTS database81 was 
used to assign proteins to subcellular localisations. Protein network visualization was performed using Cytoscape 
(version 3.3.0)82. DAVID (Database for Annotation, Visualization and Integrated Discovery)83 was used to 
identify over-represented KEGG pathways54–56 (threshold count, 2; EASE score, 0.05) and REVIGO84 was used 
for identification and visualisation of over-represented GO terms. Kinases upstream of the identified PDGF-
regulated phosphopeptides were predicted using Kinase Enrichment Analysis (KEA)57.
Reagents and antibodies. Antibodies against CRMP2 (#9393), CRMP2 Thr514 (#9397), and 
phospho-threonine (#9381) were purchased from Cell Signaling Technology (Danvers, MA). Antibodies against 
ERK1/2 (sc-514302) and ERK Thr202/Tyr204 (sc-136521) were purchased from Santa Cruz Biotechnology 
(Dallas, TX), and against tubulin (T6199) from Sigma-Aldrich Company Ltd (U.K.). The anti-Alix antibody was a 
gift from Carl Hendrik Heldin (Ludwig Institute for Cancer Research, Uppsala, Sweden)85. Goat anti-mouse-IgG 
IRDye-conjugated antibody (925-68070) and goat anti-rabbit-IgG (925-68071) HRP-conjugated antibodies were 
from LI-COR Biosciences (Lincoln, NE). Recombinant human PDGF-BB (#8912) was purchased from Cell 
Signaling Technology and okadaic acid was purchased from Calbiochem (Hertfordshire, UK).
Cell culture. Mouse embryonic fibroblasts (MEFs) were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 10 mg/mL streptomycin, and 
250 μg/mL amphotericin B. For growth factor stimulation experiments, cells were grown to 80% confluence and 
starved for 16 h in serum-free DMEM before being treated with 20 ng/mL recombinant PDGF-BB at 37 °C. In 
some experiments, cells were incubated with either 0.01 μM, 1 μM or 1.5 μM okadaic acid.
Cell lysis and immunoblotting. Cell lysates were prepared, separated by SDS-PAGE, transferred to nitro-
cellulose membranes and immunoblotted using previously described protocols18. Immunoblots were visual-
ised using fluorescence detection on the Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln NE). 
Densitometric analysis was carried out using ImageJ86.
RNA interference. Cells were transiently transfected with 80 pmol of SMARTpool or individual 
ONTARGETplus siRNA for murine CRMP2 (L-041965-01-0005, J-041965-09-002, J-041965-10-002, J-041965-
11-002; Dharmacon, Lafayette, CO) using Lipofectamine RNAiMAX (Life Technologies, Paisley, UK) as 
described elsewhere87. Nonsilencing control (NSC) siRNA was used as a control for each experiment.
Scratch wound assay. Cells were plated in 96-well cell culture plates and cultured to confluency. Cells 
were serum starved overnight. Scratch wounds were made using an automated wound maker (Essen BioScience, 
Hertfordshire, UK), cells were stimulated with 20 ng/ml PDGF, and images collected at hourly intervals 
post-wounding using an IncuCyte ZOOM imaging system (Essen BioScience, Hertfordshire, UK).
Data Availability. The mass spectrometry proteomics data, including the output from MaxQuant88, used 
in this analysis have been previously deposited on the Proteome Xchange Consortium via the PRIDE partner 
repository with the dataset identifier PXD00254518, 21.
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